Corcept Therapeutics Incorporated (CORT) 주식 분석

회사 개요

Corcept Therapeutics Incorporated is a biopharmaceutical firm focused on the discovery and development of therapeutic medications designed to address severe endocrinologic, oncologic, metabolic, and neurologic disorders within the United States market. The company operates specifically within the Healthcare sector and the Biotechnology industry, positioning itself to capitalize on opportunities for novel drug candidates targeting complex disease states. Its current scale is defined by a market capitalization of $4.49B, an annual revenue of $761.41M, and an operational workforce of 730 employees. These financial metrics indicate that Corcept holds a substantial market position, generating significant revenue streams relative to its employee base while maintaining a valuation that reflects investor confidence in its pipeline and existing commercial products like Korlym.

재무 건전성

The company reported total revenue of $761.41M over the trailing twelve months, resulting in a net income of $98.17M and an EBITDA of $45.95M, revealing a cost structure where operational expenses significantly impact bottom-line profitability despite high gross margins. The generation of $114.19M in free cash flow provides the company with substantial financial flexibility to fund research and development initiatives or manage capital allocation without relying heavily on external financing. Margin analysis shows a gross margin of 98.3%, indicating highly scalable production costs typical of biotechnology, contrasted by an operating margin of 2.2% and a profit margin of 13.1%, which highlights the substantial overhead required for R&D and commercialization before reaching net income. The balance sheet appears conservative given that cash reserves of $372.15M far exceed total debt of $6.11M, supported by a debt-to-equity ratio of 0.94 which suggests a moderate level of leverage rather than aggressive borrowing. Short-term liquidity is robust as evidenced by a current ratio of 2.92, indicating the firm holds nearly three times the assets required to cover its short-term obligations. Return on equity stands at 15.0% while return on assets is 3.3%, suggesting that management is effectively utilizing shareholder equity to generate returns, although asset utilization remains modest relative to the heavy asset-light nature of biotech firms.

밸류에이션 평가

Valuation metrics display a trailing P/E ratio of 51.52 and a forward P/E of 26.27, implying that the market expects earnings growth sufficient to narrow the valuation multiple over the coming years as forward expectations are more than half of the historical trailing multiple. The price-to-book ratio is calculated at 6.91, indicating that the market values the company at nearly seven times its net asset book value, reflecting a significant premium assigned to its intangible assets such as intellectual property and patent portfolios. Alternative valuation metrics further illustrate the company's standing with a price-to-sales ratio of 5.90 and an EV/EBITDA of 89.85, suggesting investors are pricing in high growth potential despite current profitability constraints. The stock has traded within a 52-week range bounded by a high of $91.00 and a low of $28.66, meaning the current price sits below the yearly peak but well above the yearly trough, demonstrating significant volatility over the past year. The beta value of 0.25 indicates that the stock exhibits low price volatility relative to the broader market, moving with much less sensitivity to general market swings compared to large-cap equities.

Growth & Income

Revenue growth for the trailing twelve months stands at 11.1%, while earnings growth is reported at -21.6%, revealing that earnings are contracting significantly faster than top-line sales, which implies increasing operational costs or one-time expenses are compressing profitability in the current period. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all generated earnings to reinvest into research, development, and commercial expansion rather than distributing cash to shareholders. This reinvestment strategy is typical for biotechnology firms in the growth phase where capital is directed toward advancing clinical trials and expanding market share for products like Korlym. Overall, the growth and income profile is characterized by strong top-line expansion that is currently outpacing earnings growth, while the absence of a dividend program signals a capital allocation priority focused on organic growth and pipeline development.